Compare VNDA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNDA | AVXL |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.9M | 397.6M |
| IPO Year | 2006 | N/A |
| Metric | VNDA | AVXL |
|---|---|---|
| Price | $7.05 | $3.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $14.00 | ★ $22.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 02-12-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,074,000.00 | N/A |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $21.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.12 | N/A |
| 52 Week Low | $3.81 | $2.86 |
| 52 Week High | $7.25 | $14.44 |
| Indicator | VNDA | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 67.61 | 33.60 |
| Support Level | $6.75 | $3.56 |
| Resistance Level | $7.20 | $4.88 |
| Average True Range (ATR) | 0.47 | 0.31 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 87.77 | 6.06 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.